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R E D U C ING SE RUM INSUL IN AND OVARIA N CY TOC H ROME P450c17a IN POLYCYSTIC OVA RY SY ND ROME

DECREASES IN OVARIAN CYTOCHROME P450c17 a ACTIVITY AND SERUM
FREE TESTOSTERONE AFTER REDUCTION OF INSULIN SECRETION
IN POLYCYSTIC OVARY SYNDROME
JOHN E. NESTLER, M.D.,

AND

ABSTRACT
Background Insulin resistance and increased
ovarian cytochrome P450c17a activity are both features of the polycystic ovary syndrome. P450c17a,
which is involved in androgen biosynthesis, has
both 17a-hydroxylase and 17,20-lyase activities.
Increased activity of this enzyme results in exaggerated conversion of progesterone to 17a-hydroxyprogesterone in response to stimulation by gonadotropin. We hypothesized that hyperinsulinemia
stimulates ovarian P450c17a activity.
Methods We measured serum steroid concentrations during fasting and the response of serum
17a-hydroxyprogesterone to leuprolide, a gonadotropin-releasing hormone agonist, and performed
oral glucose-tolerance tests before and after oral administration of either metformin (500 mg three times
daily) or placebo for four to eight weeks in 24 obese
women with the polycystic ovary syndrome.
Results In the 11 women given metformin,
the mean (SE) area under the serum insulin
curve after oral glucose administration decreased
from 93031603 to 4982911 mU per milliliter per
minute (5610 to 306 nmol per liter per minute)
(P  0.004). This decrease was associated with a
reduction in the basal serum 17a-hydroxyprogesterone concentration from 13521 to 667 ng
per deciliter (4.10.6 to 2.00.2 nmol per liter)
(P  0.01) and a reduction in the leuprolide-stimulated peak serum 17a-hydroxyprogesterone concentration from 45554 to 28152 ng per deciliter
(13.71.6 to 8.51.6 nmol per liter) (P  0.01). The
serum 17a-hydroxyprogesterone values increased
slightly in the placebo group. In the metformin
group, the basal serum luteinizing hormone concentration decreased from 8.52.2 to 2.80.5 mlU per
milliliter (P  0.01), the serum free testosterone concentration decreased from 0.340.07 to 0.190.05
ng per deciliter (123 to 72 pmol per liter)
(P  0.009), and the serum sex hormone–binding
globulin concentration increased from 0.80.2 to
2.30.6 mg per deciliter (297 to 8021 nmol per liter) (P0.001). None of these values changed significantly in the placebo group.
Conclusions In obese women with the polycystic
ovary syndrome, decreasing serum insulin concentrations with metformin reduces ovarian cytochrome
P450c17a activity and ameliorates hyperandrogenism. (N Engl J Med 1996;335:617-23.)
©1996, Massachusetts Medical Society.

DANIELA J. JAKUBOWICZ, M.D.

T

HE polycystic ovary syndrome is characterized by anovulation and hyperandrogenism. It affects approximately 6 percent
of women of reproductive age.1 Insulin resistance accompanied by compensatory hyperinsulinemia is a common feature of the syndrome, and
both obese and nonobese women with the syndrome
are more insulin-resistant and hyperinsulinemic than
age- and weight-matched normal women.2-9
Hyperinsulinemia may play a pathogenetic part in
hyperandrogenism in women with the polycystic
ovary syndrome by increasing ovarian androgen production and decreasing the serum sex hormone–
binding globulin concentration.10-17 Serum free testosterone concentrations decline in women with the
polycystic ovary syndrome when their insulin secretion is reduced by the administration of diazoxide15
or metformin18 or by diet.19,20 Furthermore, the observation that adolescent girls with hyperandrogenism have insulin resistance9 suggests that hyperinsulinemia may play an early and central part in the
pathogenesis of the polycystic ovary syndrome.
Cytochrome P450c17a is a bifunctional enzyme
that has both 17a-hydroxylase and 17,20-lyase activities, and it is a key enzyme in the biosynthesis of
ovarian androgens. In ovarian theca cells, P450c17a
converts progesterone to 17a-hydroxyprogesterone
through its 17a-hydroxylase activity, and then converts 17a-hydroxyprogesterone to androstenedione through its 17,20-lyase activity. Androstenedione is then converted to testosterone by the enzyme
17b-reductase (Fig. 1).
Many women with the polycystic ovary syndrome
have increased ovarian cytochrome P450c17a activity,21,22 as evidenced by increased 17a-hydroxylase
and, to a lesser extent, 17,20-lyase activity, resulting
in excessive ovarian androgen production. In these
women, a hallmark of increased ovarian P450c17a
activity is an exaggerated serum 17a-hydroxyprogesterone response to stimulation by gonadotropin-

From the Departments of Internal Medicine, Obstetrics and Gynecology, and Pharmacology and Toxicology, Division of Endocrinology and Metabolism, Medical College of Virginia, Virginia Commonwealth University,
Richmond (J.E.N.); and the Department of Internal Medicine, Hospital de
Clinicas Caracas, Caracas, Venezuela (D.J.J.). Address reprint requests to
Dr. Nestler at the Medical College of Virginia, P.O. Box 980111, Richmond, VA 23298-0111.

Vol ume 335

Numbe r 9

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 16, 2015. For personal use only. No other uses without permission.
Copyright © 1996 Massachusetts Medical Society. All rights reserved.



617

The New England Journal o f Me di c i ne

releasing hormone agonists, such as nafarelin,21-23
buserelin,24 and leuprolide.25 Whether the increased
ovarian P450c17a activity in women with the polycystic ovary syndrome is an inherited or an acquired
phenomenon is not known.
We hypothesized that hyperinsulinemia stimulates
ovarian cytochrome P450c17a activity in women
with the polycystic ovary syndrome (Fig. 1) and that
amelioration of insulin resistance in these women
would return the activity of the enzyme toward normal. To test this hypothesis, we measured the basal
serum 17a-hydroxyprogesterone concentration and
the serum 17a-hydroxyprogesterone response to the
administration of leuprolide in obese women with
the polycystic ovary syndrome before and after the
administration of metformin, which inhibits the production of hepatic glucose and enhances the sensitivity of peripheral tissue to insulin, thereby decreasing insulin secretion.26,27
METHODS
Subjects
We enrolled 25 women who were 18 to 35 years old, 24 of
whom completed the study. All the women had the polycystic
ovary syndrome, as defined by oligomenorrhea (fewer than six
menstrual periods in the previous year) and hyperandrogenemia
(elevated serum free testosterone concentrations), and were obese

(body-mass index [weight in kilograms divided by the square of the
height in meters], 27.5). All had hirsutism, and 15 had acanthosis
nigricans. Two women had each delivered two children, five women had each delivered one child, and the rest were childless. All had
normal serum prolactin concentrations and normal results on thyroid-function tests. Late-onset congenital adrenal hyperplasia was
ruled out by a morning serum 17a-hydroxyprogesterone concentration of less than 200 ng per deciliter (6 nmol per liter). All the
women had findings on ultrasonography of the ovaries that were
consistent with the diagnosis of the polycystic ovary syndrome.28
None had taken any medications for at least two months, and none
had diabetes mellitus. Twelve women were randomly assigned to
receive metformin (Glafornil, North Medicamenta, Caracas, Venezuela) and 13 women to receive placebo. The study was approved
by the institutional review board of the Hospital de Clinicas Caracas, and each woman gave informed consent.
Study Protocol
The women were evaluated during the follicular phase of the
menstrual cycle, as determined by a serum progesterone concentration of less than 2 ng per milliliter (6.4 nmol per liter). On day
1 the women came to the hospital after a 12-hour overnight fast,
and their weight, height, waist-to-hip ratio, and blood pressure
while supine were measured. Blood samples were drawn at 8:30,
8:45, and 9 a.m., and equal volumes of serum were pooled for
the measurement of insulin, glucose, steroids, and sex hormone–
binding globulin. At 9 a.m., 75 g of dextrose (Glycolab, Relab
Laboratory, Caracas, Venezuela) was given orally. Blood samples
were collected for determinations of serum glucose and insulin
concentrations at 60 and 120 minutes.
On day 2 the women ate breakfast at 9 a.m. and then fasted
until 2 p.m., when a leuprolide stimulation test was performed.
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Figure 1. Possible Mechanisms of Insulin Stimulation of Ovarian Cytochrome P450c17a Activity and Androgen Production.
In theca cells, insulin may directly stimulate (plus signs) ovarian cytochrome P450c17a, resulting in increased 17ahydroxylase and, to a lesser extent, 17,20-lyase activity. This would lead to increased production of androstenedione,
which is then converted to testosterone by the enzyme 17b-reductase. Alternatively or in conjunction with this, insulin
may stimulate ovarian androgen production indirectly by enhancing the amplitude of serum luteinizing hormone (LH)
pulses, and luteinizing hormone may then stimulate ovarian cytochrome P450c17a activity.
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After this test the women took 500 mg of metformin or placebo
orally three times daily. They were instructed not to alter their
usual eating habits, physical activity, or lifestyle during the study.
The women returned for studies four to eight weeks later, after
a low serum progesterone value had confirmed that they were in
the follicular phase of the menstrual cycle. Five women had serum
progesterone values in the postovulatory range after taking metformin for four weeks. One of them became pregnant despite
long-standing infertility; she was dropped from the study and her
results were omitted from the analysis. The remaining four women
continued to take metformin and were studied four weeks later
when their serum progesterone values were low. In the placebo
group, one woman had a serum progesterone value in the postovulatory range after four weeks; she was studied again two weeks
later.
Leuprolide Stimulation Test
After base-line blood samples had been obtained at 2 p.m. on
day 2, leuprolide (10 mg per kilogram of body weight; Lupron,
Abbott Laboratories, Takeda, Japan) was administered subcutaneously. Blood samples for the measurement of serum luteinizing
hormone were collected immediately before and 0.5, 1, 16, 20,
and 24 hours after leuprolide was administered. Blood samples
for the measurement of serum 17a-hydroxyprogesterone were
collected immediately before and 16, 20, and 24 hours after leuprolide was administered. The women ate an evening meal on day
2 but fasted thereafter until the completion of the test. The early
response of serum luteinizing hormone was determined from
pooled equal volumes of serum taken at 0.5 and 1 hour, and the
late serum luteinizing hormone response from pooled equal volumes of serum taken at 16, 20, and 24 hours. The serum concentration of 17a-hydroxyprogesterone measured immediately before the administration of leuprolide was considered the basal
value, and the highest serum concentration of 17a-hydroxyprogesterone that was measured after the administration of leuprolide was considered the peak value.
Assays
The blood samples were centrifuged immediately, and the serum was stored at 20°C until it was assayed. The serum free testosterone concentration was determined by radioimmunoassay
(Diagnostic Products, Los Angeles). All other hormones and sex
hormone–binding globulin (measured as protein) were assayed as
previously described.15,17,29 To avoid variation among assays, all
samples were analyzed in duplicate in a single assay for each hormone. The intraassay coefficients of variation for the insulin and
luteinizing hormone assays were 5.5 and 1.6 percent, respectively,
and they were less than 10 percent for all the steroid hormone
assays.
Statistical Analysis
The results are reported as means SE. Within a group, we
compared the results before treatment with those after treatment
by testing for normality with the Wilk–Shapiro test and using
Student’s two-tailed paired t-test or the Wilcoxon signed-rank
test. Comparisons between groups were made with Student’s twotailed unpaired t-test or the Mann–Whitney rank-sum test.
We analyzed the responses of serum glucose and insulin to the
oral administration of glucose and the responses of serum luteinizing hormone and 17a-hydroxyprogesterone to the administration of leuprolide by calculating the areas under the response
curves by the trapezoidal rule using absolute values.

RESULTS
Base-Line Characteristics

The women in the metformin and placebo groups
did not differ significantly in age, body-mass index,
waist-to-hip ratio, blood pressure, or serum concen-

trations of sex steroids or sex hormone–binding globulin at base line (Table 1). They also did not differ at
base line in serum insulin or glucose values measured
during fasting, insulin or glucose responses after oral
glucose administration, or basal or leuprolide-stimulated serum 17a-hydroxyprogesterone values (Table 1
and Fig. 2). The base-line serum luteinizing hormone
concentration was higher in the metformin group
than in the placebo group (8.52.2 vs. 3.70.7
mIU per milliliter; P0.04) (Fig. 3).
Anthropometric Variables

The body-mass index did not change significantly during the study in either group. The waist-to-hip
ratio decreased slightly in the metformin group
(P0.02) but did not change substantially in the
placebo group. There was no significant change in
diastolic or systolic blood pressure in either group.
Serum Insulin and Glucose Profiles

In the metformin group, the mean serum insulin
concentration measured during fasting decreased
from 173 to 92 mU per milliliter (10218 to
5412 pmol per liter) (P0.03), and the area under
the serum insulin curve decreased from 93031603
to 4982911 mU per milliliter per minute (5610
to 306 nmol per liter per minute) (P0.004) (Table 1). Neither of these values changed significantly
in the placebo group. The serum glucose concentration in fasting women did not change significantly
in either group. The area under the serum glucose
curve increased in the placebo group (P0.03) but
did not change substantially in the metformin group.
Responses of Serum Luteinizing Hormone to Leuprolide

The basal serum luteinizing hormone concentration decreased from 8.52.2 to 2.80.5 mIU per
milliliter (P0.01) in the metformin group but did
not change significantly in the placebo group (Fig.
3). The early serum luteinizing hormone responses to
leuprolide were lower after the administration of metformin than at base line (17.02.5 vs. 40.811.9
mIU per milliliter, P0.01). The late serum luteinizing hormone responses were slightly but not significantly lower after the administration of metformin (P0.26). In contrast, in the placebo group
the basal serum luteinizing hormone concentrations
and the early and late serum luteinizing hormone
responses to leuprolide were virtually identical at
base line and after the administration of placebo
(Fig. 3).
Serum 17a-Hydroxyprogesterone Responses

In the metformin group, the mean basal serum
17a-hydroxyprogesterone concentration decreased
by 51 percent, from 13521 to 667 ng per deciliter (4.10.6 to 2.00.2 nmol per liter) (P0.01),
but it did not change significantly in the placebo
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TABLE 1. CHARACTERISTICS OF WOMEN WITH THE POLYCYSTIC OVARY SYNDROME AT BASE LINE
AND AFTER THE ADMINISTRATION OF METFORMIN OR PLACEBO FOR FOUR TO EIGHT WEEKS.*
CHARACTERISTIC

METFORMIN GROUP (N11)
BASE LINE

Age (yr)
Body-mass index
Waist-to-hip ratio
Blood pressure (mm Hg)
Systolic
Diastolic
Fasting serum insulin (mU/ml)
AUC for insulin (mU/ml/min)§
Fasting serum glucose (mg/dl)
AUC for glucose (mg/dl/min)§
Serum progesterone (ng/ml)
Serum testosterone (ng/dl)
Serum free testosterone (ng/dl)
Serum androstenedione (ng/dl)
Serum 17b-estradiol (ng/dl)
Serum dehydroepiandrosterone sulfate (mg/dl)
Serum sex hormone–binding globulin (mg/dl)

PLACEBO GROUP (N13)

AFTER METFORMIN

BASE LINE

AFTER PLACEBO

291
34.11.5
0.860.01

—
34.11.3
0.850.02†

292
35.21.9
0.860.01

—
35.21.9
0.870.01

1282
871
173
9,3031603
792
11,382406
0.80.1
9017
0.340.07
32429
10.61.3
17622
0.80.2

1272
831
92‡
4,982911¶
762
11,189679
0.80.1
6814
0.190.05
28925
9.01.1
19621
2.30.6**

1324
882
285
9,0221046
834
12,224524
1.00.2
6914
0.210.05
25920
8.00.9
17019
0.80.1

1343
882
315
9,9701119
863
13,448526‡
0.80.1
8111
0.270.06
27218
8.90.7
18018
0.90.1

*The mean (SE) length of administration was 424 days in the metformin group and 322 days in the placebo
group. Plus–minus values are means SE. To convert values for insulin to picomoles per liter, multiply by 6.0; to convert
values for glucose to millimoles per liter, multiply by 0.056; to convert values for progesterone to nanomoles per liter,
multiply by 3.2; to convert values for testosterone to picomoles per liter, multiply by 34.7; to convert values for androstenedione to picomoles per liter, multiply by 34.9; to convert values for 17b-estradiol to picomoles per liter, multiply
by 36.7; to convert values for dehydroepiandrosterone sulfate to micromoles per liter, multiply by 0.027; and to convert
values for sex hormone–binding globulin to nanomoles per liter, multiply by 34.7. The normal ranges for ovulatory women are as follows: insulin, 5 to 20 mU per milliliter; progesterone, 2.0 ng per milliliter during the follicular phase; testosterone, 22 to 70 ng per deciliter; free testosterone, 0.06 to 0.19 ng per deciliter; androstenedione, 66 to 300 ng per
deciliter; 17b-estradiol, 1 to 20 ng per deciliter (early follicular to midfollicular phase); dehydroepiandrosterone sulfate,
35 to 430 mg per deciliter; and sex hormone–binding globulin, 0.6 to 4.0 mg per deciliter.
†P0.02 for the comparison with base line.
‡P0.03 for the comparison with base line.
§Values are for the area under the curve (AUC) during an oral glucose-tolerance test.
¶P0.004 for the comparison with base line.
P0.009 for the comparison with base line.
**P0.001 for the comparison with base line.

group (Fig. 2). Similarly, in the metformin group the
peak serum 17a-hydroxyprogesterone concentration after leuprolide administration decreased from
45554 to 28152 ng per deciliter (13.71.6 to
8.51.6 nmol per liter) (P0.01), and the area under the serum 17a-hydroxyprogesterone curve decreased from 7848945 to 4592766 ng per deciliter per hour (23729 to 13923 nmol per liter
per hour) (P0.004), whereas these values increased
slightly in the placebo group (Fig. 2). The change
in the area under the serum 17a-hydroxyprogesterone curve in the metformin group differed significantly from that in the placebo group (3256180
vs. 912105 ng per deciliter per hour [9827
vs. 2810 nmol per liter per hour]) (P0.001),
and the area under the serum 17a-hydroxyprogesterone curve was significantly less after metformin
administration than after placebo administration
(4592766 vs. 6949685 ng per deciliter per hour
620 

[13921 vs. 21021 nmol per liter per hour])
(P0.02).
Serum Sex Steroids

The administration of metformin was associated
with a 44 percent decrease in serum free testosterone
concentrations, from 0.340.07 to 0.190.05 ng per
deciliter (122 to 72 pmol per liter) (P0.009),
and a threefold increase in serum sex hormone–binding globulin concentrations, from 0.80.2 to 2.30.6
mg per deciliter (297 to 8021 nmol per liter)
(P0.001) (Table 1). These values did not change significantly in the placebo group. The serum concentrations of the other measured steroids did not change
substantially in either group.
DISCUSSION

In these women with the polycystic ovary syndrome, the administration of metformin reduced the
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Figure 2. Mean (SE) Serum 17a-Hydroxyprogesterone Concentrations in Women with the Polycystic Ovary Syndrome at
Base Line and after the Administration of Metformin or Placebo for Four to Eight Weeks.
Metformin was administered for a mean (SE) of 424 days,
and placebo for 322 days. The women were studied before
and after the administration of leuprolide (10 mg per kilogram).
To convert values for 17a-hydroxyprogesterone to nanomoles
per liter, multiply by 0.03. AUC denotes area under the curve.

Figure 3. Mean (SE) Serum Luteinizing Hormone Concentrations in Women with the Polycystic Ovary Syndrome at Base
Line and after the Administration of Metformin or Placebo for
Four to Eight Weeks.
Metformin was administered for a mean (SE) of 424 days,
and placebo for 322 days. The women were studied before
and after administration of leuprolide (10 mg per kilogram).
The asterisks indicate P0.01 for the comparison with the
base-line value in same group, and the dagger indicates P0.04
for the comparison with the base-line value in the metformin
group.

serum insulin concentration during fasting and the
insulin response to oral glucose administration. Concomitantly, ovarian cytochrome P450c17a activity
decreased, as demonstrated by a substantial reduction in the response of serum 17a-hydroxyprogesterone to the administration of leuprolide (to increase
luteinizing hormone secretion). The reduction in
P450c17a activity was accompanied by a decline in

the serum free testosterone concentration. These
findings suggest that increased ovarian cytochrome
P450c17a activity in women with the polycystic
ovary syndrome is due to stimulation by insulin (Fig.
1) and can be reversed by reducing the secretion of
insulin. We intentionally did not screen the women
for the presence of insulin resistance or increased
P450c17a activity so that our results would be apVol ume 335
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plicable to unselected women with the polycystic
ovary syndrome.
We cannot exclude the possibility that the decrease
in ovarian P450c17a activity resulted from the reduction in serum free testosterone or a direct action
of metformin, but these possibilities seem remote.
Hyperandrogenism is a consequence of increased
ovarian P450c17a activity and is therefore unlikely
to be the cause of the stimulated enzyme activity.
Hyperandrogenism in women with the polycystic
ovary syndrome is ameliorated by diazoxide15 — a
drug structurally unrelated to metformin that suppresses insulin release and worsens glucose tolerance
— and by diet.19,20 The common factor among these
diverse therapies appears to be the reduction in serum insulin concentrations. Because diazoxide is not
known to alter insulin sensitivity yet lowers serum
testosterone concentrations in women with the polycystic ovary syndrome,15 hyperandrogenism in such
women appears to be related to hyperinsulinemia itself and not to insulin resistance; moreover, insulin
stimulates ovarian androgen production in vitro.11-14
The recent report by Moghetti et al.30 that hyperinsulinemia may stimulate cytochrome P450c17a activity in another steroidogenic tissue of women with
the polycystic ovary syndrome — namely, the adrenal
glands — further supports our findings.
The early and late serum luteinizing hormone responses to leuprolide after the administration of placebo were almost identical to those at base line.
In contrast, the administration of metformin was
associated with decreased basal and leuprolide-stimulated serum luteinizing hormone concentrations.
These observations raise the possibility that insulin
enhances both the endogenous (basal) and the exogenous (leuprolide-stimulated) release of luteinizing hormone mediated by gonadotropin-releasing
hormone and that increased ovarian cytochrome
P450c17a activity in women with the polycystic
ovary syndrome may be related to an insulin-induced
abnormality in the dynamics of gonadotropin secretion rather than (wholly or partially) to direct stimulation of ovarian steroidogenesis by insulin (Fig.
1). Insulin receptors have been identified in human
pituitary tissue,31 and insulin augments the release
of luteinizing hormone by cultured rat pituitary
cells.32
The secretion of luteinizing hormone is often increased in women with the polycystic ovary syndrome,33 and the diurnal changes in the serum concentrations of luteinizing hormone and insulin in
these women follow a similar time course.34 Preliminary studies suggest that insulin enhances the amplitude of serum luteinizing hormone pulses but not
their frequency in obese women with the polycystic
ovary syndrome (unpublished data). An alternative
possibility is that the reduction in luteinizing hormone secretion in the women we studied was due to
622 

a decrease in the concentration of circulating androgens. However, raising serum androgen concentrations by parenteral administration in normal women35
or women with the polycystic ovary syndrome36
does not stimulate the secretion of luteinizing hormone. Finally, some of the women in our study who
received metformin ovulated, and ovulation itself may
influence the dynamics of gonadotropin secretion.37
However, in our study the results in the women who
had ovulated and those who had not were similar.
The metformin-induced reduction in insulin secretion was associated with substantial decreases in
serum free testosterone concentrations and increases
in serum sex hormone–binding globulin concentrations. In women with the polycystic ovary syndrome,
insulin stimulates ovarian androgen production11-15
and lowers serum sex hormone–binding globulin
concentrations.16,17 Our findings, and those of an
uncontrolled trial18 of metformin in women with the
polycystic ovary syndrome, support these observations. In contrast, Crave et al. found that neither serum testosterone nor sex hormone–binding globulin
concentrations changed in women with the polycystic ovary syndrome who were treated with a hypocaloric diet and metformin for four months.38 The
reasons for the discrepancies among these studies are
unknown.
In summary, our findings suggest that two features of the polycystic ovary syndrome — hyperinsulinemic insulin resistance and increased ovarian cytochrome P450c17a activity — are pathogenetically
linked, and that hyperinsulinemia stimulates this enzyme either directly or indirectly by increasing gonadotropin secretion (Fig. 1). The ability of insulin to
stimulate ovarian cytochrome P450c17a is probably
limited to women with the polycystic ovary syndrome
and may be a heritable abnormality, since many other
obese women who also are hyperinsulinemic have
neither hyperandrogenism nor hyperresponsiveness
to gonadotropin-releasing hormone.22 The clinical
implication of these results is that therapeutic measures directed at lowering insulin secretion in women
with the polycystic ovary syndrome should ameliorate their hyperandrogenism.
Supported in part by grants (RO1AG11227 and RO1CA64500) from
the National Institutes of Health (to Dr. Nestler).
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